<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 · Science · 4,427 citations
https://doi.org/10.1126/science.1141478
K
Kreshnik Zejnullahu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
68
Papers
9.5K
Citations
13
h-index
13
i10-index
Kreshnik Zejnullahu is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & HER2/EGFR in Cancer Research & Cytokine Signaling Pathways and Interactions. The author has an h-index of 13, co-authored 58 publications.
Papers by this author
worksActivation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
2011 · Science Translational Medicine · 661 citations
https://doi.org/10.1126/scitranslmed.3002442
Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma
2015 · eLife · 198 citations
https://doi.org/10.7554/elife.06907
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat